Drug Study Finds Cypher, Taxus Stents Equally Safe

Law360, New York (February 4, 2008, 12:00 AM EST) -- An 18-month trial comparing the use of the first two commercially available drug-eluting stents, Boston Scientific Corp.'s Taxus and Johnson & Johnson's Cypher, indicated that neither stent was more likely to cause adverse outcomes such as heart attack or cardiac death.

The study, compiled by the University of Copenhagen, Denmark, could help restore confidence in the use of drug-coated stents, which have received greater scrutiny in recent months from the U.S. Food and Drug Administration in response to safety concerns.

Anders M. Gall√łe, M.D., of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.